Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of prednisone on docetaxel exposure in metastatic prostate cancer
NL-OMON22101Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of docetaxel and prednisone in prostate cancer (PCa) (2 arms), sponsored by Erasmus MC. Primary endpoint: Docetaxel pharmacokinetic exposure. Started Sep 2016; status: active, not recruiting.
02
Drugs
docetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON22101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22101.